Truist Securities Reiterates Buy on Viking Therapeutics, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Joon Lee has reiterated a Buy rating on Viking Therapeutics (NASDAQ:VKTX) and maintained a price target of $32.
December 04, 2023 | 3:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities analyst Joon Lee reaffirmed a Buy rating on Viking Therapeutics and maintained a $32 price target.
The reiteration of a Buy rating and the maintenance of a $32 price target by a Truist Securities analyst could lead to increased investor confidence in Viking Therapeutics, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100